Premium
Aspirin resistance in secondary stroke prevention
Author(s) -
Berrouschot J.,
Schwetlick B.,
Twickel G.,
Fischer C.,
Uhlemann H.,
Siegemund T.,
Siegemund A.,
Roessler A.
Publication year - 2006
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.2005.00419.x
Subject(s) - aspirin , medicine , stroke (engine) , platelet , secondary prevention , clinical trial , prospective cohort study , mechanical engineering , engineering
Background – We investigated the platelet function in stroke patients treated with aspirin [acetylsalicylic acid (ASA)] for secondary stroke prevention during a follow‐up period of 1 year. Methods – In this prospective study 291 patients with first initiated aspirin therapy (300 mg/day) for secondary stroke prevention were included. Platelet aggregation measurements were performed 24 h, 3, 6, and 12 months after starting medication. Results – Twenty‐one of 291 patients (7.2%) were identified as primary ASA‐non‐responders (initial insufficient platelet inhibition) and 4.1% as secondary ASA‐non‐responders (insufficient platelet inhibition during follow‐up). There were no significant differences between ASA‐responders and ASA‐non‐responders concerning age, gender, risk factors, and stroke characteristics. Conclusion – Aspirin resistance in stroke patients is not uncommon. The clinical usefulness of routine platelet function tests needs to be proved by further trials.